AzurRx BioPharma Announces First Patients Dosed in Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis
13 août 2020 08h00 HE
|
AzurRx BioPharma, Inc.
First three patients enrolled in dose escalation trial using delayed-release enteric capsulesTopline data expected in 1H 2021 NEW YORK, Aug. 13, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc....
AzurRx BioPharma Announces Positive Interim Data From First Patient Cohort in Phase 2 Clinical Trial of MS1819 in Combination with PERT Therapy in the Treatment of Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency
11 août 2020 16h01 HE
|
AzurRx BioPharma, Inc.
Data from first five patients demonstrate positive results with primary efficacy and secondary safety endpoints achievedClinically meaningful improvement (>80%) in coefficient of fat absorption...
AzurRx BioPharma Initiates Phase 2b Clinical Trial of MS1819 in Cystic Fibrosis – with First Patient Screened and Three Clinical Trial Sites Activated
22 juil. 2020 08h00 HE
|
AzurRx BioPharma, Inc.
Three OPTION 2 clinical trial sites activated in the U.S.Topline data expected in Q1 2021 NEW YORK, July 22, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the...
AzurRx BioPharma Closes $15.2 Million Private Placement and $6.9 Million Convertible Note Exchange
20 juil. 2020 08h00 HE
|
AzurRx BioPharma, Inc.
Private placement resulting in gross cash proceeds of $15.2 million to advance two Phase 2 clinical trials of MS1819 in patients with cystic fibrosisExchange of $6.9 million principal amount of...
AzurRx BioPharma Announces Entry into Packaging, Labeling and Distribution Agreement with Creapharm Clinical Supplies for MS1819 Clinical Trial Drug Product
07 mai 2020 08h00 HE
|
AzurRx BioPharma, Inc.
NEW YORK, May 07, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies...
AzurRx BioPharma Receives Approximately $721,000 for its 2019 CIR (French Research Tax Credit)
05 mai 2020 08h00 HE
|
AzurRx BioPharma, Inc.
Received ~$2.52 million in aggregate CIR payments in 2020CIR to be used to fund on-going MS1819 Phase 2 clinical studies in Europe NEW YORK, May 05, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma,...
AzurRx BioPharma Receives Insititutional Review Board Approval to Commence its Phase 2 OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis
30 avr. 2020 08h00 HE
|
AzurRx BioPharma, Inc.
IRB protocol approval provides green-light to initiate trial at U.S. clinical sites NEW YORK, April 30, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”),...
AzurRx BioPharma Receives Approval to Conduct its Phase 2 OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis Therapeutics Development Network Sites
29 avr. 2020 08h00 HE
|
AzurRx BioPharma, Inc.
On track to initiate the OPTION 2 trial by the end of Q2 2020OPTION 2 trial to compare efficacy of standard of care to 2.2 and 4.4 gram doses of MS1819 in enteric capsulesTrial completion and top-line...
AzurRx BioPharma Announces Initiation of Phase II OPTION Clinical Trial of MS1819-SD in Cystic Fibrosis Patients
19 déc. 2018 08h00 HE
|
AzurRx BioPharma, Inc.
First site initiated at the Cystic Fibrosis InstituteInitial top line data expected in 2019 NEW YORK, Dec. 19, 2018 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the...
AzurRx BioPharma to Acquire Payment Rights to Lead Drug Candidate MS1819-SD from Protea Biosciences Group
12 déc. 2018 08h00 HE
|
AzurRx BioPharma, Inc.
NEW YORK, Dec. 12, 2018 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies...